DRUG ADMINISTRATION
A. Procarbazine is given orally as a single daily dose or in 3 or 4 divided doses. B. Lomustine 1. Lomustine is given orally as a single dose. 2. The drug should be taken on an empty stomach (1 hour before or 2 hours after eating). 3. Take at bedtime 30 to 60 minutes after taking an antiemetic. 4. Although not well documented in the literature, some clinicians believe taking lomustine at bedtime reduces the incidence and/or severity of nausea. C. Vincristine is administered as a short (10 to 15 minute) intravenous (IV) infusion.
SUPPORTIVE CARE

A. Acute and Delayed Emesis Prophylaxis:
The PCV regimen is predicted to cause acute emesis in 30% to more than 90% of patients. [34] [35] [36] [37] [38] The studies reviewed reported nausea or vomiting in 5% to 80% of patients. [3] [4] [5] 13, 15, 20 Prophylactic antiemetic therapy with a serotonin antagonist is recommended. [35] [36] [37] [38] One of the following regimens given 30 minutes prior to therapy is recommended: Note: IV = intravenous; PO = oral. Volume 52, February 2017 procarbazine is given. A meta-analysis of several trials of serotonin antagonists recommends against prolonged (greater than 24 hours) use of these agents, making a steroid, or steroid and dopamine antagonist combination, most appropriate with the procarbazine. 39 One of the following regimens is recommended: Patients who experience significant nausea or vomiting with one of these regimens should receive an agent from a different pharmacologic category. [34] [35] [36] [37] [38] There is no evidence that substituting granisetron for ondansetron in subsequent treatment cycles or increasing the dose, even to very high doses, is effective. This approach is not recommended. [40] [41] [42] [43] [44] B. Breakthrough Nausea and Vomiting [34] [35] [36] [37] [38] : Patients should receive a prescription for an antiemetic to treat breakthrough nausea. One of the following regimens is recommended: 
C. Hematopoietic Growth Factors:
Accepted practice guidelines and pharmaco economic analysis suggest that an antineoplastic regimen have a greater than 20% incidence of febrile neutropenia before prophylactic use of colony stimulating factors (CSFs) is warranted. For regimens with an incidence of febrile neutropenia between 10% and 20%, use of CSFs should be considered. For regimens with an incidence of febrile neutropenia less than 10%, routine prophylactic use of CSFs is not recommended. 45, 46 The incidence of febrile neutropenia reported in the PCV trials reviewed was only 1% 20 ; prophylactic use of CSFs is not recommended. 45 
MAJOR TOXICITIES
Most of the toxicities listed below are presented according to their degree of severity. Higher grades represent more severe toxicities. Although there are several grading systems for cancer chemotherapy toxicities, all are similar. One of the frequently used systems is the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (http:// evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf). Oncologists generally do not adjust doses or change therapy for grade 1 or 2 toxicities but make, or consider, dosage reductions or therapy changes for grade 3 or 4 toxicities. Incidence values are rounded to the nearest whole percent unless incidence was less than or equal to 0.5%. Greater than or equal to 3,000 cells/ mcL. 6, 9, 15 c. Greater than or equal to 2,000 cells/mcL. 8 2. Absolute neutrophil count (ANC):
A. Cardiovascular:
a. Within normal limits. 1 b. Greater than or equal to 1500 cells/mcL. 13 c. Greater than 500 cells/mcL. 20 
Platelet count:
a. Within normal limits. 1 b. Greater than or equal to 100,000 cells/ mcL. 6, 9, 15 c. Greater than or equal to 125,000 cells/ mcL. 8, 13 d. Greater than 50,000 cells/mcL. 20 
Hemoglobin:
a. Within normal limits. 1 b. Greater than or equal to 10 g/dL. 6,9 5 . Serum creatinine: a. Within normal limits. 1 b. Less than or equal to 1.5 mg/dL. 13 c. Less than 120 mmol/L (~1.36 mg/dL). 15 6. Serum bilirubin: a. Within normal limits. 1 b. Less than 25 mmol/L (~1.47 mg/dL). 15 c. Less than or equal to 1.5 times the ULN. 8,13 7. AST/ALT: a. Within normal limits. 1 b. Less than or equal to 2 times the upper limit of normal (ULN). 13 8. ALT: Less than or equal to 2 times the ULN. 8 In clinical practice, a pretreatment ANC of 1,000 cells/mcL and platelets of 75,000 cells/mcL are usually considered acceptable. 51 
DOSAGE MODIFICATIONS
A. Renal Function
Vincristine:
a. Bilirubin greater than 3 times the ULN, reduce dose 50%. 54 b. Bilirubin greater than or equal to 1.5 mg/ dL and less than or equal to 3 mg/dL or ALT/AST 2 to 3 times the ULN, reduce dose 50%. 55 ,56 C. Myelosuppression 1. WBC: a. Greater than or equal to 3,000 cells/mcL and less than or equal to 3,900 cells/mcL, reduce lomustine and procarbazine dose 25%. 6 b. Less than 3,000 cells/mcL 6 :
(1) Do not give lomustine or procarbazine.
(2) When toxicity resolves, reduce lomustine and procarbazine dose 25%. c. Less than 1,000 cells/mcL, reduce procarbazine dose 67%. 12 2. ANC: Less than or equal to 500 cells/mcL, reduce lomustine and procarbazine dose 25%. 20 3. Platelet count: a. Greater than or equal to 75,000 cells/mcL and less than or equal to 120,000 cells/ mcL, reduce lomustine and procarbazine dose 25%. 6 b. Less than 75,000 cells/mcL 6 :
(1) Do not give lomustine or procarbazine. (2) When toxicity resolves, reduce lomustine and procarbazine dose 25%. c. Less than 50,000 cells/mcL, reduce procarbazine dose 67%. 12 d. Less than or equal to 50,000 cells/mcL, reduce lomustine and procarbazine dose 25%. 20 
Hemoglobin:
a. Greater than or equal to 10 g/dL and less than or equal to 11.9 g/dL, reduce lomustine and procarbazine dose 25%. 6 b. Less than 10 g/dL 6 :
(2) When toxicity resolves, reduce lomustine and procarbazine dose 25%.
